ENT DISORDER TREATMENT MARKET ANALYSIS

ENT Disorder Treatment Market, by Treatment Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type (Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), by Organ Type (Ear, Nose, and Throat), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI1326
Pages :161
Formats :
Excel and PDF
Industry : Medical Devices

Leading Companies

Major players operating in the global ENT disorder treatment market include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddy’s Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc. and Zounds,Inc.

Ent Disorder Treatment Market Report Snapshots